Advertisement

Doxyval

Main information

  • Trade name:
  • Doxyval 500 mg/g Powder for Use in Drinking Water for Pigs and Chickens
  • Available from:
  • Ceva Animal Health Ltd
  • Pharmaceutical form:
  • Powder for use in drinking water
  • Prescription type:
  • POM-V - Prescription Only Medicine – Veterinarian
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug
Advertisement

Documents

Localization

  • Available in:
  • Doxyval 500 mg/g Powder for Use in Drinking Water for Pigs and Chickens
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Chickens, Pigs
  • Therapeutic area:
  • Antimicrobial

Other information

Advertisement

Status

  • Source:
  • VMD - Veterinary Medicines Directorate
  • Authorization status:
  • Authorized
  • Authorization number:
  • 15052/4095
  • Authorization date:
  • 06-09-2011
  • Last update:
  • 21-12-2016

Summary of Product characteristics

Advertisement

Revised: July 2016

AN: 01402/2015

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Doxyval 500 mg/g powder for use in drinking water for pigs and chickens

Sogedoxy 500 mg/g powder for use in drinking water for pigs and chickens (CZ)

Doxyval Vet (DK)

Doxyval 433 mg/g powder for use in drinking water for pigs and chickens (FR)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Per gram:

Active substance:

Doxycycline hyclate 500 mg

(equivalent to 433 mg doxycycline base)

Excipients:

For the full list of excipients, see section 6.1

3 PHARMACEUTICAL FORM

Powder for use in drinking water

Yellow to pale yellow powder

4 CLINICAL PARTICULARS

4.1 Target species

Pigs and chickens (broiler, pullet, breeder).

4.2 Indications for use, specifying the target species

Pigs: For the treatment of the clinical signs associated with porcine respiratory

disease caused by Actinobacillus pleuropneumoniae, Pasteurella multocida, and

Mycoplasma hyopneumoniae susceptible to doxycycline.

Chickens: Where clinical disease is present in the flock, to reduce mortality, morbidity,

and clinical signs and to reduce lesions due to Pasteurellosis caused by Pasteurella

multocida or to reduce morbidity and lesions in respiratory infections caused by

Ornithobacterium rhinotracheale (ORT).

4.3 Contraindications

Do not use in case of hypersensitivity to the active substance or to any of excipients.

Do not use in animals with an impaired liver function.

4.4 Special warnings for each target species.

None.

4.5 Special precautions for use

Page 1 of 6

Revised: July 2016

AN: 01402/2015

Special precautions for use in animals

Due to likely variability (time, geographical) in susceptibility of bacteria for

doxycycline, especially susceptibility of A. pleuropneumoniae and O. rhinotracheale

may differ from country to country and even farm to farm, bacteriological sampling

and susceptibility testing are recommended. Use of the product should be based on

culture and sensitivity of micro-organisms from diseased cases on farm. If this is not

possible, therapy should be based on local (regional, farm level) epidemiological

information about susceptibility of the target bacteria.

As eradication of the target pathogens may not be achieved, medication should

therefore be combined with good management practices, e.g. good hygiene, proper

ventilation, no overstocking.

Special precautions to be taken by the person administering the veterinary

medicinal product to animals

If you know you are allergic to the tetracycline class of antibiotics, special care should

be taken when handling this product or the medicated solution.

During preparation and administration of the medicated drinking water, skin contact

with the product and inhalation of dust particles should be avoided. Wear

impermeable gloves (e.g. rubber or latex) and an appropriate dust mask (e.g.

disposable half-mask respirator conforming to European Standard EN149) when

applying the product.

In the event of eye or skin contact, rinse the affected area with large amounts of

clean water and if irritation occurs, seek medical attention. Wash hands and

contaminated skin immediately after handling the product.

If you develop symptoms following exposure such as skin rash, you should seek

medical advice and show this warning to the physician. Swelling of the face, lips or

eyes, or difficulty with breathing are more serious symptoms and require urgent

medical attention.

Do not smoke, eat or drink while handling the product.

Take measures to avoid producing dust when incorporating the product into water.

Avoid direct contact with skin and eyes when handling the product to prevent

sensitisation and contact dermatitis.

4.6 Adverse reactions (frequency and seriousness)

Tetracyclines may - in very rare cases (less than 1 animal in 10,000 animals,

including isolated report) - induce photosensitivity and allergic reactions. If suspected

adverse reactions occur, treatment should be discontinued. Inform your veterinary

surgeon if adverse reactions occur that are not stated.

4.7 Use during pregnancy, lactation or lay

Doxycycline has a low affinity for forming complexes with calcium and studies have

demonstrated that doxycycline scarcely affects skeleton formation. No negative

effects were observed in poultry after the administration of therapeutic doses of

doxycycline.

In the absence of specific studies the use of the product is not recommended during

pregnancy or lactation.

4.8 Interaction with other medicinal products and other forms of

interaction

Page 2 of 6

Revised: July 2016

AN: 01402/2015

Do not combine with antibiotics that are bacteriocidal e.g. penicillins or

cephalosporins.

Absorption of doxycycline can be decreased in the presence of high quantities of

calcium, iron, magnesium or aluminium in the diet. Do not administered together with

antacids, kaolin and iron preparations.

It is advised that the interval between the administration of other products containing

polyvalent cations should be 1-2 hours because they limit the absorption of

tetracyclines.

Doxycycline increases the action of anticoagulants.

The solubility of the product is pH dependent and will precipitate if mixed in alkaline

solution.

Do not store the drinking water in metallic containers.

4.9 Amounts to be administered and administration route

Administration orally with the drinking water.

The recommended dose in pigs is:

12.5 mg doxycycline hyclate (25 mg product) per kg body weight per day for 4

consecutive days. If no improvement in clinical signs is seen within this time, the

diagnosis should be reviewed and treatment changed. In case of severe infections

the medication period may be prolonged for a maximum of 8 consecutive days as

determined by the attending veterinary surgeon.

The recommended dose in chickens is: 10 mg doxycycline hyclate (20 mg product)

per kg body weight per day for 3-4 consecutive days in case of infections caused by

P. multocida and

20 mg doxycycline hyclate (40 mg product) per kg body weight per day for 3-4

consecutive days in case of infections caused by O. rhinotracheale.

Based on the dose to be used, and the number and weight of the animals to be

treated, the exact daily amount of product can be calculated. The following formula

can be used to calculate the concentration of the product in drinking water:

mg product / kg body weight /

day x Mean body weight (kg) of

animals to be treated = .... mg product

per l drinking

water Mean daily water consumption (l) per animal

To ensure a correct dosage body weight should be determined as accurately as

possible. The uptake of medicated drinking water depends on the clinical condition of

the pigs/chickens. In order to obtain the correct dosage the concentration of

doxycycline has to be adjusted accordingly. The use of suitably calibrated weighing

equipment is recommended if part packs are used. The daily amount is to be added

to the drinking water such that all medication will be consumed in 24 hours.

Medicated drinking water should be refreshed or replaced every 24 hours. It is

recommended to prepare a concentrated pre-solution - approximately 100 grams

product per litre drinking water - and to dilute this further to therapeutic

concentrations if required. Alternatively, the concentrated solution can be used in a

proportional water medicator. Solubility of the product is pH dependent and it may

precipitate if it is mixed in hard alkaline drinking water. Use at minimum

concentrations of 200 mg powder per litre drinking water in areas with hard alkaline

drinking water (hardness above 10.2 °d and pH more than 8.1). During the treatment

period animals should not have access to other water sources than the medicated

water.

Page 3 of 6

Revised: July 2016

AN: 01402/2015

4.10 Overdose (symptoms, emergency procedures, antidotes), if

necessary

Overdoses up to 1.6 times the label recommended dose resulted in no clinical signs

that could be attributed to treatment. Poultry tolerate double overdoses of

doxycycline (40 mg/kg body weight) without any clinical effect.

4.11 Withdrawal periods

Pigs:

- Meat and offal: 4 days

Chickens:

- Meat and offal: 3 days, following a dose rate of 10 mg/kg body weight for 4 days.

- Meat and offal: 9 days, following a dose rate of 20 mg/kg body weight for 4 days.

- Eggs: Not authorised for use in laying birds producing eggs for human consumption.

Do not use within 4 weeks of onset of the laying period

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Antibacterial for systemic use - Tetracycline.

ATC vet code: QJ01AA02

5.1 Pharmacodynamic properties

Doxycycline belongs to the group of the tetracycline antibiotics. These antibiotics

have a broad spectrum of antimicrobial activity, sharing the same basic structure of

polycyclic naphthacenecarboxamide.

Doxycycline is primarily a bacteriostatic drug. It exerts its action by inhibiting the

protein synthesis of the bacterial cell. Inhibition of bacterial protein synthesis results

in disturbance of all functions necessary for the life of bacteria. Especially cell-division

and the formation of the cell wall are impaired.

Doxycycline is a broad-spectrum antibiotic, active against a large number of Gram-

positive and Gram-negative, aerobe and anaerobe micro-organisms such as

Mycoplasma hyopneumoniae and Pasteurella multocida.For Ornithobacterium

rhinotracheale results demonstrate a great variation from high to low susceptibility,

depending on the geographical region where isolates came from.

In pig pathogens resistance against doxycycline may also vary; especially

susceptibility figures of A. pleuropneumoniae may differ from country to country and

even farm to farm.

Four resistance mechanisms acquired by microorganisms against tetracyclines in

general have been reported: Decreased accumulation of tetracyclines (decreased

permeability of the bacterial cell wall and active efflux), protein protection of the

bacterial ribosome, enzymatic inactivation of the antibiotic and rRNA mutations

(preventing the tetracycline binding to ribosome). Tetracycline resistance is usually

acquired by means of plasmids or other mobile elements (e.g. conjugative

transposones). Cross resistance between tetracyclines has also been described. Due

to the greater liposolubility and greater facility to pass through cell membranes (in

comparison to tetracycline), doxycycline retains a certain degree of efficacy against

microorganisms with acquired resistance to tetracyclines.

5.2 Pharmacokinetic particulars

Page 4 of 6

Revised: July 2016

AN: 01402/2015

Doxycycline is absorbed in the stomach and the first part of the duodenum.

Compared to the older tetracyclines the absorption of doxycycline is less affected by

the presence of bivalent cations in food. Bioavailability in non-fasted pigs is

approximately 21%.

Following oral administration at a dose of 12.8 mg/kg body weight, steady state

concentrations during medication range between a C

min of 0.40 μg/ml in the early

morning to a C

max of 0.87 μg/ml in the late afternoon in pigs.

Following administration of doxycycline hyclate at an actual dose of 21 mg/kg body

weight to chickens mean plasma concentrations above 1 μg/ml were reached within 6

hours and lasted for 6 hours after cessation of medication. From 24 h up to 96 h after

start of treatment the doxycycline plasma concentrations exceeded 2 μg/ml.

Following administration of doxycycline hyclate at an actual dose of 10 mg/kg body

weight steady state plasma concentrations ranged from 0.75 to 0.93 μg/g between

12 and 96 hours after start of medication.

Because doxycycline is highly lipid soluble, it has a good tissue penetration.

Respiratory tract tissue: plasma ratios of 1.3 (healthy lungs), 1.9 (pneumonic lungs)

and 2.3 (nasal mucosa) have been reported for doxycycline. Plasma protein binding

is high (over 90%).

Doxycycline is scarcely metabolised. Doxycycline is primarily excreted with the

faeces.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Silica colloidal anhydrous

Citric acid anhydrous

6.2 Incompatibilities

Solubility of doxycycline is pH dependent. Precipitation will occur in an alkaline

solution. In the absence of compatibility studies, this veterinary medicinal product

must not be mixed with other veterinary medicinal products.

6.3 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 2 years

Shelf-life after first opening the immediate packaging: 1 year

Shelf-life after dilution or reconstitution according to directions: 24 hours after dilution

in drinking water.

6.4. Special precautions for storage

This veterinary medicinal product does not require any special conditions.

6.5 Nature and composition of immediate packaging

Nature of container:

Bags formed by polyester, aluminium and polyethylene.

Package sizes:

100 g, 10 x 100 g, 1000 g and 2500 g.

Not all pack sizes may be marketed.

Page 5 of 6

Revised: July 2016

AN: 01402/2015

6.6 Special precautions for the disposal of unused veterinary medicinal

product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such

veterinary medicinal product should be disposed of in accordance with local

requirements.

7. MARKETING AUTHORISATION HOLDER

Ceva Animal Health Ltd

Unit 3, Anglo Office Park

White Lion Road

Amersham

Buckinghamshire

HP7 9FB

8. MARKETING AUTHORISATION NUMBER

Vm 15052/4095

9. DATE OF FIRST AUTHORISATION

06 September 2011

10. DATE OF REVISION OF THE TEXT

July 2016

06 July 2016

Page 6 of 6

There are no safety alerts related to this product.

There are no news related to this product.

Other products from the same company

Advertisement